Immatics Nv logo

Immatics Nv share price today

(IMTX)

Immatics Nv share price is $7.28 & ₹624.70 as on 7 Jan 2025, 2.30 'hrs' IST

$7.28

▲

0.11

(1.53%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Immatics Nv share price in Dollar and Rupees. Guide to invest in Immatics Nv stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Immatics Nv, along with analyst recommendations, forecasts, and comprehensive financials.

Immatics Nv share price movements

  • Today's Low: $7.08
    Today's High: $7.35

    Day's Volatility :3.61%

  • 52 Weeks Low: $6.68
    52 Weeks High: $13.77

    52 Weeks Volatility :51.49%

Immatics Nv Returns

PeriodImmatics NvSector (Health Care)Index (Russel 2000)
3 Months
-34.64%
-8.4%
0.0%
6 Months
-41.47%
-3.8%
0.0%
1 Year
-33.86%
-0.1%
0.0%
3 Years
-41.04%
2.9%
-19.8%

Immatics Nv Key Statistics

in dollars & INR

Previous Close
$7.17
Open
$7.18
Today's High
$7.345
Today's Low
$7.08
Market Capitalization
$864.2M
Today's Volume
$981.1K
52 Week High
$13.77
52 Week Low
$6.68
Revenue TTM
$70.9M
EBITDA
$-95.2M
Earnings Per Share (EPS)
$-0.63
Profit Margin
-104.01%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-24.32%

How to invest in Immatics Nv from India?

It is very easy for Indian residents to invest directly in Immatics Nv from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Immatics Nv stock in both Indian Rupees (INR) and US Dollars (USD). Search for Immatics Nv or IMTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Immatics Nv or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Immatics Nv shares which would translate to 0.118 fractional shares of Immatics Nv as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Immatics Nv, in just a few clicks!

Returns in Immatics Nv for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Immatics Nv investment value today

Current value as on today

₹70,381

Returns

₹29,619

(-29.62%)

Returns from Immatics Nv Stock

₹32,841 (-32.84%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Immatics Nv

43%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Immatics Nv on INDmoney from India has grown in the last 30 days as on Jan 7, 2025. 43% more investors are searching Immatics Nv in the last 30 days versus the previous period.

Global Institutional Holdings in Immatics Nv

  • RTW INVESTMENTS, LLC

    8.23%

  • Wellington Management Company LLP

    7.96%

  • Perceptive Advisors LLC

    6.65%

  • T. Rowe Price Investment Management,Inc.

    6.07%

  • Baker Bros Advisors LP

    5.30%

  • Paradigm Biocapital Advisors LP

    3.21%

Analyst Recommendation on Immatics Nv

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Immatics Nv(by analysts ranked 0 to 5 stars)

Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Immatics Nv

What analysts predicted

Upside of 130.08%

Current:

$7.28

Target:

$16.75

Insights on Immatics Nv

  • Price Movement

    In the last 3 months, IMTX stock has moved down by -34.0%

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 18.75M → 50.55M (in $), with an average increase of 62.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -18.02M → -8.57M (in $), with an average increase of 110.3% per quarter

  • IMTX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 54.9%

  • IMTX vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 96.5%

  • Price to Sales

    ForIMTX every $1 of sales, investors are willing to pay $9.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Immatics Nv Financials in INR & Dollars

FY18Y/Y Change
Revenue
$4.3M
-
Net Income
$-35.8M
-
Net Profit Margin
-834.06%
-
FY19Y/Y Change
Revenue
$20.5M
↑ 389.36%
Net Income
$-35.3M
↑ 0.94%
Net Profit Margin
-172.05%
↑ 662.01%
FY20Y/Y Change
Revenue
$38.0M
↑ 69.4%
Net Income
$-279.0M
↑ 622.56%
Net Profit Margin
-733.84%
↓ 561.79%
FY21Y/Y Change
Revenue
$39.3M
↑ 11.23%
Net Income
$-107.5M
↓ 58.55%
Net Profit Margin
-273.45%
↑ 460.39%
FY22Y/Y Change
Revenue
$182.9M
↑ 397.17%
Net Income
$39.7M
↓ 139.46%
Net Profit Margin
21.71%
↑ 295.16%
FY23Y/Y Change
Revenue
$58.9M
↓ 68.76%
Net Income
$-105.8M
↓ 358.55%
Net Profit Margin
-179.63%
↓ 201.34%
Q2 FY23Q/Q Change
Revenue
$24.2M
↑ 128.2%
Net Income
$-26.7M
↑ 62.73%
Net Profit Margin
-110.09%
↑ 44.29%
Q3 FY23Q/Q Change
Revenue
$6.3M
↓ 73.49%
Net Income
$-28.3M
↑ 7.64%
Net Profit Margin
-447.0%
↓ 336.91%
Q4 FY23Q/Q Change
Revenue
$17.4M
↑ 168.66%
Net Income
$-28.5M
↓ 1.29%
Net Profit Margin
-164.24%
↑ 282.76%
Q1 FY24Q/Q Change
Revenue
$33.1M
↑ 91.24%
Net Income
$-3.3M
↓ 88.25%
Net Profit Margin
-10.09%
↑ 154.15%
Q2 FY24Q/Q Change
Revenue
$20.2M
↓ 38.4%
Net Income
$-19.4M
↑ 486.66%
Net Profit Margin
-96.09%
↓ 86.0%
Q3 FY24Q/Q Change
Revenue
$50.6M
↑ 169.58%
Net Income
$-8.6M
↓ 52.45%
Net Profit Margin
-16.95%
↑ 79.14%
FY18Y/Y Change
Profit
$4.3M
-
FY19Y/Y Change
Profit
$-24.0M
↓ 674.06%
FY20Y/Y Change
Profit
$-43.6M
↑ 65.57%
FY21Y/Y Change
Profit
$-59.7M
↑ 47.39%
FY22Y/Y Change
Profit
$69.9M
↓ 225.07%
FY23Y/Y Change
Profit
$-70.5M
↓ 197.9%
Q2 FY23Q/Q Change
Profit
$-5.4M
↓ 72.09%
Q3 FY23Q/Q Change
Profit
$-26.2M
↑ 395.1%
Q4 FY23Q/Q Change
Profit
$-18.9M
↓ 29.41%
Q1 FY24Q/Q Change
Profit
$-1.8M
↓ 90.43%
Q2 FY24Q/Q Change
Profit
$20.1M
↓ 1223.55%
Q3 FY24Q/Q Change
Profit
$50.6M
↑ 170.95%
FY18Y/Y Change
Operating Cash Flow
$23.5M
-
Investing Cash Flow
$-15.4M
-
Financing Cash Flow
$26.9M
-
FY19Y/Y Change
Operating Cash Flow
$78.9M
↑ 243.1%
Investing Cash Flow
$-5.6M
↓ 62.56%
Financing Cash Flow
$-2.1M
↓ 107.87%
FY20Y/Y Change
Operating Cash Flow
$-104.1M
↓ 220.63%
Investing Cash Flow
$-19.4M
↑ 215.26%
Financing Cash Flow
$252.9M
↓ 11264.5%
FY21Y/Y Change
Operating Cash Flow
$-92.5M
↓ 4.47%
Investing Cash Flow
$8.5M
↓ 146.98%
Financing Cash Flow
$-3.0M
↓ 101.26%
FY22Y/Y Change
Operating Cash Flow
$106.0M
↓ 222.43%
Investing Cash Flow
$-222.0M
↓ 2899.83%
Financing Cash Flow
$130.9M
↓ 4834.4%
Q2 FY23Q/Q Change
Operating Cash Flow
$-7.2M
↓ 72.14%
Investing Cash Flow
$-18.3M
↑ 352.7%
Financing Cash Flow
$39.5M
↓ 4309.12%

Immatics Nv Technicals Summary

Sell

Neutral

Buy

Immatics Nv is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Immatics Nv Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immatics Nv
Immatics Nv
-7.84%
-41.47%
-33.86%
-41.04%
-52.36%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immatics Nv
Immatics Nv
15.24
NA
NA
-0.69
-0.24
-0.12
NA
2.66
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immatics Nv
Immatics Nv
Buy
$864.2M
-52.36%
15.24
-104.01%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Immatics Nv

immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics'​ proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l
Organization
Immatics Nv
Employees
542
CEO
Dr. Harpreet Singh Ph.D.
Industry
Health Technology

Management People of Immatics Nv

NameTitle
Dr. Harpreet Singh Ph.D.
CEO, MD, Member of Management Board & Executive Director
Dr. Toni Weinschenk Ph.D.
Co-Founder & Chief Innovation Officer
Mr. Arnd Christ MBA
Chief Financial Officer
Mr. Steffen Walter Ph.D.
Chief Operations Officer
Mr. Edward A. Sturchio
General Counsel & Secretary
Dr. Carsten Reinhardt M.D., Ph.D.
Chief Development Officer
Mr. Cedrik M. Britten M.D.
Chief Medical Officer
Mr. Jordan Silverstein
Head of Strategy
Dr. Hans-Georg Rammensee Ph.D.
Co-Founder & Member of the Scientific Advisory Board
Mr. Ephraim Hofsäß M.Sc.
Vice President of SEC Reporting & Accounting

Important FAQs about investing in Immatics Nv from India :

What is Immatics Nv share price today?

Immatics Nv share price today stands at $7.28, Open: $7.18 ; Previous Close: $7.17 ; High: $7.35 ; Low: $7.08 ; 52 Week High: $13.77 ; 52 Week Low: $6.68. The stock opens at $7.18, after a previous close of $7.17. The stock reached a daily high of $7.35 and a low of $7.08, with a 52-week high of $13.77 and a 52-week low of $6.68.

Can Indians buy Immatics Nv shares?

Yes, Indians can invest in the Immatics Nv (IMTX) from India.

With INDmoney, you can buy Immatics Nv at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Immatics Nv at zero transaction cost.

How can I buy Immatics Nv shares from India?

It is very easy to buy Immatics Nv from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Immatics Nv be purchased?

Yes, you can buy fractional shares of Immatics Nv with INDmoney app.

What are the documents required to start investing in Immatics Nv stocks?

To start investing in Immatics Nv, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Immatics Nv

Today’s highest price of Immatics Nv (IMTX) is $7.35.

Today’s lowest price of Immatics Nv (IMTX) is $7.08.

What is today's market capitalisation of Immatics Nv

Today's market capitalisation of Immatics Nv IMTX is 864.2M

What is the 52 Week High and Low Range of Immatics Nv

  • 52 Week High

    $13.77

  • 52 Week Low

    $6.68

What are the historical returns of Immatics Nv?

  • 1 Month Returns

    -7.84%

  • 3 Months Returns

    -41.47%

  • 1 Year Returns

    -33.86%

  • 5 Years Returns

    -52.36%

Who is the Chief Executive Officer (CEO) of Immatics Nv

Dr. Harpreet Singh Ph.D. is the current Chief Executive Officer (CEO) of Immatics Nv.